Enabling solid tumor T cell therapies and checkpoint inhibitors with oncolytic adenoviruses

Oncolytic viruses developed to specifically destroy tumor cells are a potent form of immunotherapy, and consequently are finding their place in immunotherapy combination regimens. TILT Biotherapeutics’ oncolytic viruses enable solid tumor T cell therapy and checkpoint-inhibiting antibodies.

Like Comment
Page of
Go to the profile of Tilt Biotherapeutics

Tilt Biotherapeutics

TILT Biotherapeutics, founded in 2013, is a leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses. The company’s patented technology is used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR-T) and checkpoint inhibiting antibody therapy. TILT has secured almost 10M€ in funding and is now setting up phase I clinical trials, where its approach is further evaluated in cancer patients.

No comments yet.